Imaging the immune response to monitor tumor immunotherapy

Expert Review of Vaccines

Volumn 8, Issue 10, 2009, Pages 1427-1437

  Wang, Qin ^b   Ornstein, Moshe ^c   Kaufman, Howard L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Biologic therapy; Cancer; Imaging; Immune monitoring; Vaccine

Indexed keywords

CANCER VACCINE; FLUORODEOXYGLUCOSE F 18; T LYMPHOCYTE ANTIGEN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL LABELING; CELL MIGRATION; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL MICROSCOPY; EX VIVO STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO CULTURE; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR REJECTION; TUMOR VOLUME;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CELL MOVEMENT; DIAGNOSTIC IMAGING; FLOW CYTOMETRY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MAGNETIC RESONANCE IMAGING; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; T-LYMPHOCYTES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70349932630     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.100     Document Type: Review

References (68)

1. Girkin JM, Poland S, Wright AJ. Adaptive optics for deeper imaging of biological samples. Curr. Opin Biotechnol. 20, 106-110 (2009).
2. Schulz RB, Semmler W. Fundamentals of optical imaging. Handb. Exp. Pharmacol. 185, 3-22 (2008).
3. Messa C, Bettinardi V, Picchio M et al. PET/CT in diagnostic oncology. Q. J. Nucl. Med. Mol. Imaging 48 (2), 66-75 (2004).
4. Heron DE, Andrade RS, Beriwal S, Smith RP. PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response. Am. J. Clin. Oncol. 31 (4), 352-362 (2008).
5. Toner GC, Hicks RJ. PET for sarcomas other than gastrointestinal stromal tumors. Oncologist 13 (Suppl. 2), 22-26 (2008).
6. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol. 188 (6), 1622-1635 (2007).
7. Chen CY, Li CW, Kuo YT et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants - initial experience. Radiology 239, 448-456 (2006).
8. Einarsdottir H, Karlsson M, Wejde J, Bauer HC. Diffusion-weighted MRI of soft tissue tumours. Eur. Radiol. 14, 959-963 (2004).
9. Koh DM, Scurr E, Collins D et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. Am. J. Roentgenol. 188, 1001-1008 (2007).
10. Oh J, Henry RG, Pirzkall A et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J. Magn. Reson. Imaging 19, 546-554 (2004).
11. Theilmann RJ, Borders R, Trouard TP et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasm 6, 831-837 (2004). (Pubitemid 40041502)
12. Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. Clin. Cancer Res. 14, 3832-3839 (2008).
13. Long CM, van Laarhoven HW, Bulte JW, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res. 69, 3180-3187 (2009).
14. Shafer-Weaver K, Rosenberg S, Strobl S, Gregory Alvord W, Baseler M, Malyguine A. Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials. J. Immunother. 29, 328-335 (2006). (Pubitemid 44297301)
15. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin. Cancer Res. 12, 2346S-2352S (2006).
16. + T lymphocytes by structural and functional assays. Cancer Immunol. Immunother. 257, 289-302 (2008).
17. Barve M, Bender J, Senzer N et al. Induction of immune responses and clinical efficacy in a Phase II trial of 1DM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J. Clin. Oncol. 26, 4418-4425 (2008).
18. Kaufman HL, Taback B, Sherman W et al. Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J. Transl. Med. 7, 2 (2009).
19. Denk W, Strickler JH, Webb WW. Two-photon laser scanning fluorescence microscopy. Science 248, 73-76 (1990). (Pubitemid 20139273)
20. Bousso P. T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat. Rev. Immunol. 8, 675-684 (2008).
21. Bousso P, Bhakta NR, Lewis RS, Robey E. Dynamics of thymocyte-stromal cell interactions visualized by two-photon microscopy. Science 296, 1876-1880 (2002).
22. Miller MJ, Wei SH, Parker I, Cahalan MD. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 296, 1869-1873 (2002).
23. Stoll S, Delon J, Brotz TM, Germain RN. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 296, 1873-1876 (2002).
24. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154-159 (2004). • First demonstration of T-cell priming by dendritic cells in vivo using two-photon microscopy.
25. + T cell activation by dendritic cells in lymph nodes. J. Exp. Med. 200, 847-856 (2004).
26. Shakhar G, Lindquist RL, Skokos D et al. Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat. Immunol. 6, 707-714 (2005).
27. Lindquist RL, Shakhar G, Dudziak D et al. Visualizing dendritic cell networks in vivo. Nat. Immunol. 5, 1243-1250 (2004).
28. Skokos D, Shakhar G, Varma R et al. Peptide-MHC potency governs dynamic interactions between T cells and dendritic cells in lymph nodes. Nat. Immunol. 8, 835-844 (2007).
29. Garrod KR, Wei SH, Parker I, Cahalan MD. Natural killer cells actively patrol peripheral lymph nodes forming stable conjugates to eliminate MHC-mismatched targets. Proc. Natl Acad. Sci. USA 104, 12081-12086 (2007).
30. Celli S, Breart B, Bousso P. Intravital two-photon imaging of natural killer cells and dendritic cells in lymph nodes. Methods Mol. Biol. 415, 119-126 (2008).
31. Allen CD, Okada T, Tang HL, Cyster JG. Imaging of germinal center selection events during affinity maturation. Science 315, 528-531 (2007). (Pubitemid 46175759)
32. Schwickert TA, Lindquist RL, Shakhar G et al. In vivo imaging of germinal centres reveals a dynamic open structure. Nature 446, 83-87 (2007).
33. Suzuki K, Grigorova I, Phan TG, Kelly LM, Cyster JG. Visualizing B cell capture of cognate antigen from follicular dendritic cells. J. Exp. Med. 206, 1485-1493 (2009).
34. Creusot RJ, Yaghoubi SS, Chang P et al. Lymphoid tissue-specific homing of bone marrow-derived dendritic cells. Blood 113, 6638-6647 (2009).
35. Leimgruber A, Berger C, Cortez-Retamozo V et al. Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasm 11, 459-468 (2009).
36. de Vries IJ, Lesterhuis WJ, Barentsz JO et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23, 1407-1413 (2005).
37. Pham W, Xie J, Gore JC. Tracking the migration of dendritic cells by in vivo optical imaging. Neoplasia 9, 1130-1137 (2007). (Pubitemid 350255360)
38. Pham W, Kobukai S, Hotta C, Gore JC. Dendritic cells: therapy and imaging. Expert Opin. Biol. Ther. 9, 539-564 (2009).
39. Cavanagh LL, Weninger W. Dendritic cell behaviour in vivo: lessons learned from intravital two-photon microscopy. Immunol. Cell Biol. 86, 428-438 (2008).
40. Verdijk P, Aarntzen EH, Lesterhuis WJ et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin. Cancer Res. 15, 2531-2540 (2009).
41. Verdijk P, Scheenen TW, Lesterhuis WJ et al. Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int. J. Cancer 120, 978-984 (2007). (Pubitemid 46214296)
42. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383-393 (2006).
43. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308 (2008). • Good review on adoptive T-cell transfer.
44. Schumacher TN, Restifo NP. Adoptive T cell therapy of cancer. Curr. Opin Immunol. 21, 187-189 (2009).
45. Akins EJ, Dubey P. Noninvasive imaging of cell-mediated therapy for treatment of cancer. J. Nucl. Med. 49 (Suppl. 2), 180S-195S (2008).
46. Palestra CJ, Love C, Bhargava KK. Labeled leukocyte imaging: current status and future directions. Q. J. Nucl. Med. Mol. Imaging 53, 105-123 (2009).
47. Ridolfi R, Riccobon A, Galassi R et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J. Transl. Med. 2, 27 (2004).
48. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat. Biotechnol. 23 (8), 983-987 (2005).
49. Agger R, Petersen MS, Petersen CC et al. T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging. J. Immunother. 30, 29-39 (2007). (Pubitemid 46052201)
50. Shu CJ, Guo S, Kim YJ et al. Visualization of a primary antitumor immune response by positron emission tomography. Proc. Natl. Acad. Sci. USA 102, 17412-17417 (2005).
51. Traversari C, Marktel S, Magnani Z et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 109, 4708-4715 (2007). (Pubitemid 46827762)
52. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107, 2294-2302 (2006). (Pubitemid 43345547)
53. Ponomarev V, Doubrovin M, Shavrin A et al. A human-derived reporter gene for noninvasive imaging in humans: mitochondrial thymidine kinase type 2. J. Nucl. Med. 48, 819-826 (2007).
54. Nair-Gill ED, Shu CJ, Radu CG, Witte ON. Non-invasive imaging of adaptive immunity using positron emission tomography. Immunol. Rev. 221, 214-228 (2008).
55. Ridolfi R, Riccobon A, Galassi R et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J. Transl. Med. 2, 27 (2004).
56. Matsui K, Wang Z, McCarthy TJ, Allen PM, Reichert DE. Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET. Nucl. Med. Biol. 31, 1021-1031 (2004).
57. Pittet MJ, Grimm J, Berger CR et al. In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc. Natl Acad. Sei. USA 104, 12457-12461 (2007).
58. Bernhard H, Neudorfer J, Gebhard K et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 57, 271-280 (2008).
59. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol. Clin. North. Am. 43, 153-167 (2005).
60. Su H, Forbes A, Gambhir SS, Braun J. Quantitation of cell number by a positron emission tomography reporter gene strategy. Mol. Imaging Biol. 6, 139-148 (2004).
61. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J. Nucl. Med. 48, 304-310 (2007).
62. Chen K, Cai W, Li ZB, Wang H, Chen X. Quantitative PET imaging of VEGF receptor expression. Mol. Imaging Biol. 11, 15-22 (2009).
63. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J. Exp. Med. 204, 345-356 (2007). • Demonstration of cytotoxic T cells within the tumor microenvironment.
64. + T cell cytotoxic activity during adoptive T cell therapy in mice. J. Clin. Invest. 118, 1390-1397 (2008).
65. Shcherbo D, Merzlyak EM, Chepurnykh TV et al. Bright far-red fluorescent protein for whole-body imaging. Nat. Methods 4, 741-746 (2007). • Demonstration of a new fluorescent protein that will improve whole-body imaging. (Pubitemid 47338169)
66. Hoffman RM. A better fluorescent protein for whole-body imaging. Trends Biotechnol. 26, 1-4 (2008).
67. Galanzha EI, Shashkov EV, Tuchin VV, Zharov VP. In vivo multispectral, multiparameter, photoacoustic lymph flow cytometry with natural cell focusing, label-free detection and multicolor nanoparticle probes. Cytometry A 73, 884-894 (2008).
68. Gerger A, Hofmann-Wellenhof R, Samonigg H, Smolle J. In vivo confocal laser scanning microscopy in the diagnosis of melanocytic skin tumours. Br. J. Dermatol. 160, 475-481 (2009). • Discussion of using confocal microscopy in vivo for clinical diagnosis.